Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline Patient Characteristics (ITT Population)

From: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

  Lumiracoxib 100 mg o.d. (n = 755) Lumiracoxib 100 mg b.i.d. (n = 1,519) Celecoxib 200 mg o.d. (n = 758)
Age (years), mean ± SD 62.9 ± 10.25 62.2 ± 10.02 62.7 ± 10.00
Females, n (%) 541 (71.7) 1081 (71.2) 531 (70.1)
BMI (kg/m2), mean ± SD 29.5 ± 6.41 29.7 ± 6.34 29.8 ± 6.33
Race, n (%)    
   White/Caucasian 712 (94.3) 1450 (95.5) 731 (96.4)
   Black/African American 22 (2.9) 45 (3.0) 13 (1.7)
   Hispanic 10 (1.3) 8 (0.5) 11 (1.5)
   Other 11 (1.5) 16 (1.1) 3 (0.4)
Disease duration (years), mean ± SD 7.9 ± 7.73 7.6 ± 7.79 7.5 ± 7.62
Target joint, n (%)    
   Hip 58 (7.7) 122 (8.0) 59 (7.8)
   Knee 376 (49.8) 743 (48.9) 350 (46.2)
   Hand 159 (21.1) 301 (19.8) 166 (21.9)
   Spine 162 (21.5) 353 (23.2) 183 (24.1)
OA pain, n (%)    
   Mild 48 (6.4) 102 (6.7) 49 (6.5)
   Moderate 363 (48.1) 704 (46.3) 346 (45.6)
   Severe 343 (45.4) 712 (46.9) 361 (47.6)
   Extreme 1 (0.1) 1 (0.1) 2 (0.3)
Patient's global assessment of disease activity, n (%)    
   Very good 2 (0.3) 8 (0.5) 4 (0.5)
   Good 94 (12.5) 167 (11.0) 78 (10.3)
   Fair 340 (45.0) 711 (46.8) 360 (47.5)
   Poor 296 (39.2) 581 (38.2) 287 (37.9)
   Very poor 23 (3.0) 51 (3.4) 29 (3.8)
Physician's global assessment of disease activity, n (%)    
   Very good 1 (0.1) 0 (0.0) 2 (0.3)
   Good 51 (6.8) 85 (5.6) 45 (5.9)
   Fair 371 (49.1) 784 (51.6) 373 (49.2)
   Poor 317 (42.0) 618 (40.7) 324 (42.7)
   Very poor 14 (1.9) 31 (2.0) 12 (1.6)
Short Arthritis assessment Scale (SAS) total score, mean ± SD 22.4 ± 7.81 22.1 ± 7.61 22.3 ± 7.86
  1. o.d. = once daily; b.i.d. = twice daily; BMI = body mass index; ITT = intention-to-treat; SD = standard deviation; Japanese, other Asian or Pacific Islander or other.